DE69915103D1 - Neue oligomere konjugate zum transfer biologischer moleküle in zellen - Google Patents

Neue oligomere konjugate zum transfer biologischer moleküle in zellen

Info

Publication number
DE69915103D1
DE69915103D1 DE69915103T DE69915103T DE69915103D1 DE 69915103 D1 DE69915103 D1 DE 69915103D1 DE 69915103 T DE69915103 T DE 69915103T DE 69915103 T DE69915103 T DE 69915103T DE 69915103 D1 DE69915103 D1 DE 69915103D1
Authority
DE
Germany
Prior art keywords
cells
transfer
organic molecules
oligomer conjugates
new oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69915103T
Other languages
English (en)
Other versions
DE69915103T2 (de
Inventor
Patrick Midoux
Chantal Pichon
Mahajoub Bello-Roufai
Michel Monsigny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDM Immuno Designed Molecules
Original Assignee
IDM Immuno Designed Molecules
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDM Immuno Designed Molecules filed Critical IDM Immuno Designed Molecules
Publication of DE69915103D1 publication Critical patent/DE69915103D1/de
Application granted granted Critical
Publication of DE69915103T2 publication Critical patent/DE69915103T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69915103T 1998-12-02 1999-11-22 Neue oligomere konjugate zum transfer biologischer moleküle in zellen Expired - Fee Related DE69915103T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98403015 1998-12-02
EP98403015 1998-12-02
PCT/EP1999/008980 WO2000032764A1 (en) 1998-12-02 1999-11-22 New oligomeric conjugates liable to transfer biological molecules into cells

Publications (2)

Publication Number Publication Date
DE69915103D1 true DE69915103D1 (de) 2004-04-01
DE69915103T2 DE69915103T2 (de) 2004-12-09

Family

ID=8235574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69915103T Expired - Fee Related DE69915103T2 (de) 1998-12-02 1999-11-22 Neue oligomere konjugate zum transfer biologischer moleküle in zellen

Country Status (8)

Country Link
EP (1) EP1135481B1 (de)
JP (1) JP2002532388A (de)
AT (1) ATE260337T1 (de)
AU (1) AU770963B2 (de)
CA (1) CA2348823A1 (de)
DE (1) DE69915103T2 (de)
ES (1) ES2213397T3 (de)
WO (1) WO2000032764A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047496A1 (en) 1999-12-29 2001-07-05 Mixson A James Histidine copolymer and methods for using same
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
IL154044A0 (en) * 2000-07-21 2003-07-31 Essentia Biosystems Inc Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2003066054A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Cationic polymers for use in therapeutic agent delivery
US7465708B2 (en) 2002-11-25 2008-12-16 Mixson A James Branched cationic copolymers and methods for antimicrobial use
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
RU2007136616A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
SG160358A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
JP2016503300A (ja) 2012-11-15 2016-02-04 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ 抗ＡｐｏＢアンチセンス複合体化合物
WO2015078995A1 (en) * 2013-11-28 2015-06-04 Institut National de la Santé et de la Recherche Médicale Agents for treating cystic fibrosis
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
AU4770093A (en) * 1992-07-02 1994-01-31 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
AU681192B2 (en) * 1993-09-28 1997-08-21 Hisamitsu Pharmaceutical Co., Inc. Polyamino acid oligonucleotide carrier
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires

Also Published As

Publication number Publication date
WO2000032764A1 (en) 2000-06-08
DE69915103T2 (de) 2004-12-09
CA2348823A1 (en) 2000-06-08
AU770963B2 (en) 2004-03-11
ES2213397T3 (es) 2004-08-16
EP1135481A1 (de) 2001-09-26
JP2002532388A (ja) 2002-10-02
ATE260337T1 (de) 2004-03-15
EP1135481B1 (de) 2004-02-25
AU1652600A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
DE69915103D1 (de) Neue oligomere konjugate zum transfer biologischer moleküle in zellen
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
EA200100365A1 (ru) Синтазы
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
EP0293852A3 (de) Organopolysiloxanzusammensetzungen, die funktionelle alpha,beta-ungesättigte Carbonylgruppen enthalten
DE60209560D1 (de) Thermoplastische zusammensetzung, welche einen hyperverzweigten polymer enthält, und daraus hergestellte gegenstände
DE69430312D1 (de) Peralkylierte oligopeptidmischungen
EP0590071A4 (en) Substantially pure receptor like tgf--g(b)1 binding molecules and uses thereof
DK1210357T3 (da) Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf
BR0211200A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
PL345561A1 (en) Substituted benzoylcyclohexandiones
EP0882454A3 (de) Herstellungsverfahren für die Konjugation von Chelaten mit Molekülen enthaltend Aminogruppen
PL336000A1 (en) Cosmetic compositions containing a cationic polymer of low molecular weight and a silicone as well as their application
AU1062997A (en) Novel polymer supports for nucleic acid synthesis
ES2154590A1 (es) Procedimiento de sintesis de peptidos en fase solida
HUP0500541A2 (hu) Rákellenes antraciklin hatóanyag célterápiára alkalmas pH-érzékeny polimer konjugátjai
CA2258802A1 (fr) Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations
CA2316113A1 (en) Method for nucleic acid purification using iodine
CA2340934A1 (en) Novel collectin
RU96106897A (ru) Рецептор глюканового активатора и кодирующая его молекула днк
IT8948114A0 (it) Mezzi leganti per composizioni di alta energia, che utilizzano il cis-, cis-1,3,5-tri (isocianatometil) cicloesano
WO2000040607A3 (en) Tiam2 (t-cell lymphoma invasion and metastasis 2) nucleotide exchange factor
DE69430261T2 (de) Thermotrope poly(esteramide)e enthaltende monomereinheiten abgeleitet aus 4,4'-biphenyldicarbonsäure
DE69801814T2 (de) Polymere amine
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee